141 related articles for article (PubMed ID: 19825945)
41. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
42. Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF and interferon-gamma.
Bausero MA; Panoskaltsis-Mortari A; Blazar BR; Katsanis E
J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):113-24. PubMed ID: 8732694
[TBL] [Abstract][Full Text] [Related]
43. Sustained cytokine production and immunophenotypic changes in human neuroblastoma cell lines transduced with a human gamma interferon vector.
Uçar K; Seeger RC; Challita PM; Watanabe CT; Yen TL; Morgan JP; Amado R; Chou E; McCallister T; Barber JR
Cancer Gene Ther; 1995 Sep; 2(3):171-81. PubMed ID: 8528960
[TBL] [Abstract][Full Text] [Related]
44. Gamma interferon transduced 9L gliosarcoma. Cytokine gene therapy and its relevance to cellular therapy with alloreactive cytotoxic T lymphocytes.
Paul DB; Read SB; Kulprathipanja NV; Gomez GG; Kleinschmidt-DeMasters BK; Schiltz PM; Kruse CA
J Neurooncol; 2003; 64(1-2):89-99. PubMed ID: 12952290
[TBL] [Abstract][Full Text] [Related]
45. B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules.
Katsanis E; Xu Z; Bausero MA; Dancisak BB; Gorden KB; Davis G; Gray GS; Orchard PJ; Blazar BR
Cancer Gene Ther; 1995 Mar; 2(1):39-46. PubMed ID: 7542553
[TBL] [Abstract][Full Text] [Related]
46. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
[TBL] [Abstract][Full Text] [Related]
47. Protective effects of interferon-gamma in intraocular herpes simplex type 1 infection do not depend on major histocompatibility complex class I or class II expression.
Geiger KD; Lee MS; Baugh C; Sarvetnick NE
J Neurovirol; 1995 Dec; 1(5-6):405-9. PubMed ID: 9222384
[TBL] [Abstract][Full Text] [Related]
48. The influence of natural killer cells in neuroblastoma.
Reynolds JV; Shou J; Choi H; Sigal R; Ziegler MM; Daly JM
Arch Surg; 1989 Feb; 124(2):235-9. PubMed ID: 2492800
[TBL] [Abstract][Full Text] [Related]
49. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
Riquelme E; Carreño LJ; González PA; Kalergis AM
Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
[TBL] [Abstract][Full Text] [Related]
50. Uncoordinate induction and differential regulation of HLA class-I and class-II expression by gamma-interferon in differentiating human neuroblastoma cells.
Ponzoni M; Guarnaccia F; Corrias MV; Cornaglia-Ferraris P
Int J Cancer; 1993 Nov; 55(5):817-23. PubMed ID: 8244579
[TBL] [Abstract][Full Text] [Related]
51. A novel co-culture assay to assess anti-tumor CD8
Olivo Pimentel V; Yaromina A; Marcus D; Dubois LJ; Lambin P
J Immunol Methods; 2020 Dec; 487():112899. PubMed ID: 33068606
[TBL] [Abstract][Full Text] [Related]
52. Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15.
Chen Y; Sun C; Landoni E; Metelitsa L; Dotti G; Savoldo B
Clin Cancer Res; 2019 May; 25(9):2915-2924. PubMed ID: 30617136
[TBL] [Abstract][Full Text] [Related]
53. Reduced recognition of metastatic melanoma cells by autologous MART-1 specific CTL: relationship to TAP expression.
Murray JL; Hudson JM; Ross MI; Zhang HZ; Ioannides CG
J Immunother; 2000 Jan; 23(1):28-35. PubMed ID: 10687135
[TBL] [Abstract][Full Text] [Related]
54. Major histocompatibility complex-restricted lysis of neuroblastoma cells by autologous cytotoxic T lymphocytes.
Sarkar AK; Burlingame SM; Zang YQ; Dulai V; Hicks MJ; Strother DR; Nuchtern JG
J Immunother; 2001; 24(4):305-11. PubMed ID: 11565832
[TBL] [Abstract][Full Text] [Related]
55. Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme.
Yang I; Kremen TJ; Giovannone AJ; Paik E; Odesa SK; Prins RM; Liau LM
J Neurosurg; 2004 Feb; 100(2):310-9. PubMed ID: 15086239
[TBL] [Abstract][Full Text] [Related]
56. Rat mammary adenocarcinoma 13762 expressing IFN-gamma elicits antitumor CD4+ MHC class II-restricted T cells that are cytolytic in vitro and tumoricidal in vivo.
Frey AB
J Immunol; 1995 May; 154(9):4613-22. PubMed ID: 7722313
[TBL] [Abstract][Full Text] [Related]
57. Mechanism of cytolytic T lymphocyte killing of a low class I-expressing tumor.
Blieden TM; McAdam AJ; Frelinger JG; Lord EM
J Immunol; 1991 Aug; 147(4):1433-8. PubMed ID: 1907998
[TBL] [Abstract][Full Text] [Related]
58. Absence of major histocompatibility complex class I on neural stem cells does not permit natural killer cell killing and prevents recognition by alloreactive cytotoxic T lymphocytes in vitro.
Mammolenti M; Gajavelli S; Tsoulfas P; Levy R
Stem Cells; 2004; 22(6):1101-10. PubMed ID: 15536199
[TBL] [Abstract][Full Text] [Related]
59. IFN-γ treatment protocol for MHC-I
Stifter K; Krieger J; Ruths L; Gout J; Mulaw M; Lechel A; Kleger A; Seufferlein T; Wagner M; Schirmbeck R
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32868392
[TBL] [Abstract][Full Text] [Related]
60. Interferon-γ up-regulates major-histocompatibility-complex class I-related chain A expression and enhances major-histocompatibility-complex class I-related chain A-mediated cytolysis of human corneal epithelium by natural killer cells in vitro.
Hong J; Shao T; Sun X; Li G; Xu J
J Interferon Cytokine Res; 2012 Mar; 32(3):115-20. PubMed ID: 22257014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
